– IRELAND, Clonmel – Shorla Pharma Limited, an Irish speciality pharmaceutical company, today announced the completion of an $8.3 million Series A financing led by Seroba Life Sciences, a European Venture Capital firm headquartered in Dublin, Ireland with additional investment from Irish and Canadian based family offices and participation from Enterprise Ireland.
As part of the financing, Alan O’Connell, a Partner at Seroba has joined the Shorla board.
“We’re delighted to support an Irish company with such a promising pipeline of products designed to improve treatment options for cancer patients. Shorla is led by experienced founders with a track record of success in the sector and we look forward to working with them to grow the company and bring their products to market,” said Alan O’Connell, Partner at Seroba and Shorla board member.
Shorla has developed innovative oncology drugs with a focus on rare, orphan and pediatric cancers, delivering more effective products in indications where existing treatments are sub-optimal for the target patients.
The company was founded by Sharon Cunningham and Orlaith Ryan, both formerly with EirGen Pharma in Waterford, Ireland. Shorla is based in Questum, a Clonmel, Ireland based acceleration centre.
Together with a strong team of scientists, clinicians and an extensive industry network, the company has an advanced pipeline of innovative drug products to treat a number of unmet patient needs. The funding will support the advancement of the product pipeline, along with the expansion of technical and commercial operations in both Ireland and the US.
Orlaith Ryan of Shorla said, “This significant investment will provide the necessary resource to further advance the product pipeline through health authority registration and commercialization which will ultimately create valuable and clinically impactful treatments that improve patient outcomes.”
Sharon Cunningham added, “Seroba is a leading venture capital firm in the global life sciences industry and they, along with other participants in the investment syndicate bring invaluable experience to Shorla and have a proven track record in the pharmaceutical sector. We’re confident that we have the right partners to support us in executing our vision.”
Julie Sinnamon, CEO, Enterprise Ireland, said, “We are delighted to support Shorla and to be part of this investment round. Ireland is widely recognised as a centre for the global life sciences industry as well as a leader in MedTech and pharmaceutical manufacturing. Helping to maintain that reputation, Shorla, led by two female founders, is a highly innovative company developing new solutions to critical issues in the oncology area. It is also particularly heartening to see this company starting in a regional location. Earlier this year, the Enterprise Ireland ‘Action Plan for Women in Business’ cited that less than 10 per cent of VC funding is going to companies with women founders. This investment is consistent with that action plan in terms of developing a larger number of companies of scale led by female founders. It is fantastic to have a role model like Shorla to demonstrate what’s possible. I wish the team luck with the project and congratulate the company on its success to date.”
About Shorla Pharma Ltd
Shorla Pharma Ltd is a privately held, Irish based speciality pharmaceutical company with an advanced pipeline of innovative oncology drugs for women’s and pediatric cancers. The company concentrates on indications where existing treatments are limited, in shortage or inadequate for the target population. Shorla’s growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care. Shorla was established by Sharon Cunningham and Orlaith Ryan in 2018 and won the overall award at Ireland’s Best Young Entrepreneur competition in 2019. Sharon and Orlaith were included on a list of 50 people to watch out for in 2020 by the Irish Times.
For more information: https://www.shorlapharma.com
About Seroba Life Sciences
Seroba is a European life sciences venture capital firm focused on investing in winning innovations in biotech and MedTech. The team has deep investment and industry experience enabling Seroba to help entrepreneurs realise their ambitions whilst creating value for investors. The firm has three funds under management and has built a portfolio of investee companies across multiple indications. Seroba partners with entrepreneurs to create and build businesses around extraordinary science.
For more information: https://www.seroba-lifesciences.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.